{"id":411798,"date":"2025-11-23T13:30:00","date_gmt":"2025-11-23T12:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=411798"},"modified":"2025-11-23T17:20:10","modified_gmt":"2025-11-23T16:20:10","slug":"new-treatment-options-for-myelofibrosis-patients-with-a-high-risk-of-anemia","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-treatment-options-for-myelofibrosis-patients-with-a-high-risk-of-anemia\/","title":{"rendered":"New treatment options for myelofibrosis patients with a high risk of anemia?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Myelofibrosis is considered one of the most complex myeloproliferative neoplasms &#8211; with high symptom burden, progressive cytopenia and limited treatment options &#8211; with anemia in particular presenting a clinical challenge that often worsens with conventional JAK inhibition. A multicenter study published in August 2025 by an Italian research team now provides care-related evidence for momelotinib as a potential disease-modifying option to restore erythropoiesis and control spleen-related symptoms. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fnew-treatment-options-for-myelofibrosis-patients-with-a-high-risk-of-anemia%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Myelofibrosis is considered one of the most complex myeloproliferative neoplasms &#8211; with high symptom burden, progressive cytopenia and limited treatment options &#8211; with anemia in particular presenting a clinical challenge&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/en\/my-account\/packages\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/en\/log-in\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fen%2Fnew-treatment-options-for-myelofibrosis-patients-with-a-high-risk-of-anemia%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411803,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Myelofibrosis  ","footnotes":""},"category":[11548,11508,11353,11370,11503],"tags":[86081,12702,86082,86080,86083,21613],"powerkit_post_featured":[],"class_list":["post-411798","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-education","category-hematology","category-oncology","category-studies","tag-acvr1-inhibitor","tag-anemia","tag-conventional-jak-inhibition","tag-jak1-2-inhibitor","tag-momelotinib","tag-myelofibrosis","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-13 01:00:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":411814,"slug":"de-nouvelles-options-therapeutiques-pour-les-patients-atteints-de-myelofibrose-a-haut-risque-danemie","post_title":"De nouvelles options th\u00e9rapeutiques pour les patients atteints de my\u00e9lofibrose \u00e0 haut risque d'an\u00e9mie ?","href":"https:\/\/medizinonline.com\/fr\/de-nouvelles-options-therapeutiques-pour-les-patients-atteints-de-myelofibrose-a-haut-risque-danemie\/"},"it_IT":{"locale":"it_IT","id":411820,"slug":"nuove-opzioni-di-trattamento-per-i-pazienti-con-mielofibrosi-ad-alto-rischio-di-anemia","post_title":"Nuove opzioni di trattamento per i pazienti con mielofibrosi ad alto rischio di anemia?","href":"https:\/\/medizinonline.com\/it\/nuove-opzioni-di-trattamento-per-i-pazienti-con-mielofibrosi-ad-alto-rischio-di-anemia\/"},"pt_PT":{"locale":"pt_PT","id":411813,"slug":"novas-opcoes-de-tratamento-para-os-doentes-com-mielofibrose-que-apresentam-um-risco-elevado-de-anemia","post_title":"Novas op\u00e7\u00f5es de tratamento para os doentes com mielofibrose que apresentam um risco elevado de anemia?","href":"https:\/\/medizinonline.com\/pt-pt\/novas-opcoes-de-tratamento-para-os-doentes-com-mielofibrose-que-apresentam-um-risco-elevado-de-anemia\/"},"es_ES":{"locale":"es_ES","id":411819,"slug":"nuevas-opciones-de-tratamiento-para-los-pacientes-con-mielofibrosis-con-alto-riesgo-de-anemia","post_title":"\u00bfNuevas opciones de tratamiento para los pacientes con mielofibrosis con alto riesgo de anemia?","href":"https:\/\/medizinonline.com\/es\/nuevas-opciones-de-tratamiento-para-los-pacientes-con-mielofibrosis-con-alto-riesgo-de-anemia\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=411798"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411798\/revisions"}],"predecessor-version":[{"id":411804,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411798\/revisions\/411804"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/411803"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=411798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=411798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=411798"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=411798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}